Case study: Hybrid advisory board on CDK 4/6 inhibitors in HR+/HER2-

The Ask

Our client wanted to uncover specialist insights from a group of 6 oncologists about their thoughts and lived clinical experiences regarding CDK 4/6 inhibitors in HR+/HER2-, given that recently published real world-evidence studies and posters had emerged in breast cancer.  

The Solution

• We ran a 6-month hybrid advisory board, based on an asynchronous component with written questions, and a virtual meeting.
• Here, we helped create, develop and moderate a series of discussion topics to share with the expert panel. Firstly, we launched two waves of asynchronous discussion on medCrowd , asking for the experts' advice. We used the responses to build a scientific summary report – this report drew out the key findings from specialists who are faced with the challenges in the breast cancer oncology space on a day-to-day basis.

• Once the findings had been summarised, we used the report to develop a discussion plan for a virtual meeting with the experts, to confirm interpretation of their responses and agree on what actions should be taken.

The Benefit

Our client was able to gain raw feedback from experts with a foot on the ground in breast cancer. Feedback was gained in a timely manner, with an understanding of the potential clinical implications of new conference data and real-word evidence. Our clients were then able to incorporate this feedback into their wider strategic goals, to ensure it remained relevant to current opinions and challenges faced by oncologists. Our hybrid approach benefited the client as they received two different types of qualitative feedback, allowing those who prefer live environments to contribute in the meeting, and those who need more time, to contribute asynchronously.